Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EI-201
- Development stage
- Phase 1
- Lead developer
- eTheRNA immunotherapies
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
EI-201 is an investigational mRNA-based immunotherapy developed by eTheRNA immunotherapies for the treatment of HPV16-positive carcinomas. It consists of mRNAs encoding the HPV16 oncoproteins E6 and E7, which are the primary biological targets, combined with eTheRNA's proprietary TriMix mRNA adjuvant. TriMix is designed to activate dendritic cells and stimulate a robust T-cell immune response against tumor cells expressing these viral antigens. The mRNA components are encapsulated in lipid nanoparticles (LNPs) to facilitate delivery to antigen-presenting cells following intravenous administration. EI-201 is currently being evaluated in Phase I/IIa clinical trials for patients with recurrent or metastatic HPV16-positive cancers, including cervical, anal, and oropharyngeal cancers.
02
Targets
CD27 (Cluster of Differentiation 27)CD40 (Cluster of differentiation 40 receptor)HPV16 E6/E7 TCR (HPV16 E6/E7-specific T-cell receptor)TLR4 (Toll-like receptor 4)CD40LG (CD40 ligand extracellular domain)CD70 (Cluster of Differentiation 70)HPV16 E6 oncoproteinHPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on EI-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EI-201.